BBIO Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an overview of BridgeBio Pharma Inc's (BBIO) financials, focusing on its profitability and key financial metrics. It highlights the company's gross margin of 94.74%, an operating margin of -83.30%, and a net margin of -126.24%. The article also includes a competitor comparison with NBIX and SMMT, noting BBIO's market capitalization of $14.18B.
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock
The article discusses the implications of insider selling at BridgeBio Pharma, suggesting it could be a bearish signal. While insider selling doesn't always precede a stock price drop, large volumes of selling can indicate a lack of confidence in future growth from those with the most information about the company. The article also provides details on the insider transactions and current stock performance.
A Look At BridgeBio Pharma (BBIO) Valuation After BBP-418 NDA And New Acoramidis Data
BridgeBio Pharma (BBIO) is gaining attention after submitting a New Drug Application for BBP-418 and releasing new acoramidis data, influencing its stock performance. Despite a strong three-year return, market analysts are divided on its current valuation, with some suggesting it is undervalued by 26% based on future growth potential, while others caution about its high P/S ratio compared to industry averages. Investors are advised to review underlying data and consider both the significant opportunities from its late-stage pipeline and potential risks.
BridgeBio to present LGMD2I/R9 trial data at MDA conference
BridgeBio Pharma, Inc. is set to present additional interim analysis data from its Phase 3 FORTIFY trial for BBP-418 in LGMD2I/R9 patients at the MDA Clinical and Scientific Conference. The presentation will cover efficacy endpoints, with further presentations from academic collaborators and posters detailing disease burden, treatment patterns, health outcomes, and BBP-418's developmental pathway. This announcement follows BridgeBio's recent report of strong fourth-quarter revenue, primarily from its Attruby treatment, despite a wider-than-expected adjusted loss.
BBIO - Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion
BridgeBio Pharma's fair value estimate has increased to $100.05, driven by strong Attruby sales and progress in its late-stage pipeline, including positive results for infigratinib in achondroplasia. While bullish analysts highlight diversification and growth potential, cautious voices point to concentration risk with Attruby as the primary revenue driver and high operating expenses. The company anticipates significant revenue and earnings growth, expecting to reach profitability by 2028, despite ongoing financial risks.
Viking funds hold 6.1% of BridgeBio Pharma (NASDAQ: BBIO)
Viking Global Investors and related entities have reported a 6.1% beneficial ownership stake in BridgeBio Pharma, Inc., consisting of 11,842,434 shares. This update, filed as Amendment No. 11 to a Schedule 13D, primarily serves to remove former advisory director David C. Ott as a reporting person following his retirement on March 31, 2026. The filing also clarifies the current group of reporting persons and their control structure, noting no additional trades since the previous amendment, except for those detailed in an exhibit.
A Look At BridgeBio Pharma (BBIO) Valuation After BBP-418 NDA And New Acoramidis Data
BridgeBio Pharma (BBIO) has submitted a New Drug Application for BBP-418 and released new acoramidis data, generating investor interest. While the company is considered 26% undervalued with a fair value of $100.05, its current P/S ratio of 28.7x is significantly higher than the industry average, signaling potential valuation risk. Investors are weighing recent momentum against a long-term significant share price gain.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
BridgeBio Pharma (NASDAQ:BBIO) has received a "Moderate Buy" consensus rating from 24 brokerages, with an average 12-month price target of $86.75. Insider transactions in the last quarter saw sales totaling approximately $16.6 million, reducing insider stakes, despite the company exceeding revenue expectations but missing EPS estimates for its recent quarter. Institutional investors have significantly increased their stakes, with 99.85% of the stock owned by them.
Allspring Global Investments Holdings LLC Has $77.78 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO
Allspring Global Investments Holdings LLC significantly increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) during Q4, acquiring 994,220 additional shares, bringing their total holding to $77.78 million, representing 0.52% of the company. BridgeBio recently reported Q4 earnings that missed estimates but showed a substantial 2521.2% year-over-year revenue increase, with the stock trading up 7.1% post-earnings. Despite positive analyst sentiment with a consensus "Moderate Buy" rating and price target of $86.75, company insiders have sold a notable amount of shares in recent months.
BridgeBio Secures Attruby Approval, Triggers Price Target Hikes
BridgeBio Pharma (NASDAQ:BBIO) has received FDA approval for Attruby (acoramidis), an oral therapy for transthyretin amyloidosis cardiomyopathy (ATTR-CM), positioning it to challenge Pfizer's market dominance. This approval and subsequent commercial momentum have led multiple Wall Street firms, including Mizuho Securities and William Blair, to raise their price targets for the stock. Analysts project significant peak annual sales for Attruby, though competition and upcoming patent litigation against Pfizer will be key factors in its market success.
BridgeBio Pharma (NasdaqGS:BBIO) Stock Forecast & Analyst Predictions
BridgeBio Pharma (BBIO) is projected to experience substantial growth, with earnings expected to increase by 61.2% and revenue by 33.7% annually. The company, which is transitioning into a commercial-stage entity with its drug Attruby, is forecast to become profitable within the next three years. This report analyzes analyst predictions, future growth forecasts, and historical financial data for BBIO.
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $111
Piper Sandler has reiterated its Buy rating on BridgeBio Pharma (BBIO.US) and maintained its price target at $111. This decision reflects the firm's continued confidence in the pharmaceutical company's future performance. The sustained rating and price target indicate that Piper Sandler expects BridgeBio Pharma to deliver strong results.
BridgeBio Files NDA for LGMD2I/R9 Oral Therapy
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for its oral therapy BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9. This filing is supported by positive interim Phase 3 data showing significant improvements in patient ambulation and pulmonary function. If approved, BBP-418 would be the first therapy for this condition and any limb-girdle muscular dystrophy, with further clinical development planned.
BridgeBio (NASDAQ: BBIO) files NDA for first potential LGMD2I/R9 treatment
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for oral BBP-418, a potential first-in-class treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The submission is supported by positive 12-month interim data from the Phase 3 FORTIFY trial, which showed significant improvements in ambulation and pulmonary function with a favorable safety profile. If approved, BBP-418 could launch in the U.S. in late 2026 or early 2027 and would be the first therapy for this specific type of muscular dystrophy, and potentially the first for any form of LGMD.
BridgeBio stock seen as core holding after muscular dystrophy filing
William Blair has reiterated its Outperform rating on BridgeBio Pharma, considering it a core small- to mid-cap biotech holding after the company submitted a New Drug Application for BBP-418 to treat limb-girdle muscular dystrophy. The drug, which showed significant efficacy and safety in Phase III trials, is projected to achieve worldwide sales of $1.1 billion by 2035, with an approval expected in late 2026 or early 2027. BridgeBio's stock has surged 99% in the past year, and analysts anticipate significant sales growth and a transition to cash flow positivity by late 2027.
BridgeBio Pharma stock drops 3.97% as NDA filed with FDA for BBP-418 therapy
BridgeBio Pharma's stock dropped 3.97% following the submission of a New Drug Application (NDA) to the FDA for its BBP-418 therapy, intended for individuals with LGMD2I/R9. Despite the short-term decline, technical analysis indicates a long-term bullish structure with mixed short-term signals and an expected price consolidation between $66.00 and $73.00 for the coming week, with a high probability of upward movement if key resistance breaks. This NDA represents a significant milestone, potentially offering the first approved therapy for this specific form of Limb-girdle muscular dystrophy and potentially for any form of LGMD.
BridgeBio seeks first approved treatment for rare muscle disease
BridgeBio Pharma (Nasdaq: BBIO) has submitted a New Drug Application (NDA) to the FDA for its oral drug BBP-418, intended to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The NDA leverages positive 12-month interim data from the Phase 3 FORTIFY trial, which demonstrated significant improvements in ambulation and pulmonary function, alongside a favorable safety profile. If approved, BBP-418 could be the first treatment for LGMD2I/R9 and potentially the first for any form of LGMD, with a U.S. launch anticipated in late 2026 or early 2027.
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for BBP-418, designed to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The submission includes positive Phase 3 data showing rapid, consistent treatment effects and a favorable safety profile, with potential approval and U.S. launch anticipated in late 2026 or early 2027. If approved, BBP-418 could be the first and only therapy for LGMD2I/R9 and potentially the first approved treatment for any form of LGMD.
BridgeBio Pharma stock price forecast: mixed signals as BBIO retreats 3.97% toward key support
BridgeBio Pharma (BBIO) stock is showing mixed signals, retreating 3.97% today despite a weekly gain, as it approaches key support levels. While short-term support is present, the stock faces medium-term downside pressure, balanced by a long-term bullish bias above major moving averages. Momentum indicators are weakening, suggesting potential for consolidation, though a significant price increase is still considered probable based on weekly signals.
How Long-Term ATTRibute-CM Data on Acoramidis Could Shape BridgeBio Pharma’s (BBIO) Investment Story
BridgeBio Pharma (BBIO) announced long-term efficacy and safety results from its Phase 3 ATTRibute-CM trial of acoramidis, presented at the American College of Cardiology Annual Scientific Sessions. This new data, focusing on survival, disease stabilization, and patient-reported outcomes, is expected to influence the clinical use of Attruby and BridgeBio's investment narrative. While the data improves Attruby's profile, investors still need to consider the company's high operating costs and reliance on a single cardiovascular asset.
BridgeBio Pharma (MIL:1BBIO) PB Ratio : (As of Mar. 28, 2026)
This article provides an analysis of BridgeBio Pharma's (MIL:1BBIO) Price-to-Book (PB) Ratio as of March 29, 2026. It explains that the company's PB Ratio is calculated by dividing its share price (€59.16) by its Book Value per Share (€-9.15), resulting in an unranked ratio in the biotechnology industry. The analysis also indicates that BridgeBio Pharma is considered undervalued by GuruFocus, with its current stock price significantly below its estimated GF Value™.
Vanguard disaggregates holdings; reports 0 Bridgebio shares (BBIO)
Vanguard has filed an amended Schedule 13G/A, reporting zero beneficial ownership of Bridgebio Pharma Inc. common stock, representing 0% ownership. This change is attributed to an internal realignment within The Vanguard Group effective January 12, 2026, which led to certain subsidiaries reporting their holdings separately. The filing clarifies that this is an administrative reporting change and does not indicate a change in Bridgebio's capitalization or control.
A Look At BridgeBio Pharma (BBIO) Valuation As New Acoramidis Phase 3 Data Draws Market Attention
BridgeBio Pharma (BBIO) is drawing market attention with new Phase 3 data for acoramidis. Although it has a strong long-term return, short-term sentiment has cooled. The stock is currently priced at US$71.61, which is considered undervalued by some analyses compared to a fair value estimate of $89.50, but its P/S ratio is high compared to its industry peers, indicating potential execution risk.
MOODY ALDRICH PARTNERS LLC's BridgeBio Pharma Inc(BBIO) Holding History
This article details MOODY ALDRICH PARTNERS LLC's holding history for BridgeBio Pharma Inc (BBIO), showing their current shares, value, and portfolio percentage. It also includes a chart of quarterly buys and sells and a list of recent articles related to BridgeBio Pharma Inc, highlighting key news and analyst ratings.
BridgeBio heart drug lands late-breaking ACC slot with survival data
BridgeBio (NASDAQ: BBIO) announced it will present long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial of acoramidis at the American College of Cardiology Annual Scientific Sessions. A late-breaking oral presentation on survival benefits and disease stabilization is scheduled for March 30, 2026, alongside three posters detailing biomarker, health-status, and real-world survey findings on March 28 and March 30. This presentation reinforces the company's focus on later-stage cardiomyopathy programs and provides investors with key insights into the drug's potential value.
BridgeBio to Present Long-Term Efficacy and Safety Data
BridgeBio Pharma, Inc. will present long-term efficacy and safety data from the ATTRibute-CM OLE trial for acoramidis at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo. The data, focusing on patients with ATTR-CM, will include a late-breaking oral presentation on survival benefits and disease stabilization, as well as three posters on additional OLE data and real-world survey findings. Acoramidis (Attruby™) is indicated for treating cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults.
BridgeBio (BBIO) CAO awarded 14,170 RSUs in new equity grant
BridgeBio Pharma, Inc.'s Chief Accounting Officer, Maricel Apuli, received an equity grant of 14,170 restricted stock units (RSUs). These RSUs will vest over time, starting May 16, 2026, and contingent on her continued employment, increasing her total direct holdings to 136,115 shares. This award serves as long-term, service-based incentive compensation.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. announced that its compensation committee approved equity grants to 29 new employees. These grants consist of restricted stock units for an aggregate of 70,916 shares of the Company's common stock. The awards were made as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
BridgeBio Pharma (BBIO) President and CFO receives 59,041 RSU equity grant
Thomas Trimarchi, President and CFO of BridgeBio Pharma (BBIO), was granted 59,041 Restricted Stock Units (RSUs) as equity compensation, as disclosed in a Form 4 SEC filing. These RSUs will vest over time, with 1/16th vesting on May 16, 2026, and quarterly thereafter, contingent on his continued service. Following this grant, Trimarchi directly holds 395,626 shares of BridgeBio common stock.
BridgeBio gives 29 new hires stock awards totaling 70,916 shares
BridgeBio Pharma announced that its compensation committee approved equity awards for 29 new employees on March 18, 2026, totaling 70,916 restricted stock units. These awards, granted as an inducement for employment under Nasdaq Listing Rule 5635(c)(4), will vest one-fourth on February 16, 2027, with the remainder vesting quarterly thereafter, contingent on continued employment. The grants are part of the company's amended equity plan and reflect ongoing hiring and compensation strategies.
BridgeBio (BBIO) CEO Neil Kumar awarded options and 104,313 RSUs
BridgeBio Pharma, Inc. CEO Neil Kumar was granted new equity awards on March 17, 2026, including stock options for 40,570 shares at an exercise price of $70.94 and 104,313 restricted stock units (RSUs). Both awards will vest in equal 1/16 installments starting May 16, 2026, and quarterly thereafter, contingent on his continued employment with the company or its subsidiaries. These compensation-related grants are detailed in a recent SEC Form 4 filing.
Mizuho raises BridgeBio Pharma stock price target on drug strength
Mizuho increased its price target for BridgeBio Pharma (NASDAQ:BBIO) to $106 from $91, maintaining an Outperform rating due to the continued strong performance of its drug Attruby and progress with infigratinib. The firm also highlighted upcoming patent litigation with Pfizer (NYSE:PFE) as a significant catalyst. InvestingPro analysis suggests the stock is undervalued, having returned 120% in the past year, while other analysts like Leerink Partners, Barclays, and William Blair also reiterated positive ratings.
BBIO: Mizuho Raises Price Target to $106, Maintains 'Outperform' Rating | BBIO Stock News
Mizuho has reaffirmed its 'Outperform' rating for BridgeBio Pharma (BBIO) and increased its price target by 16.48% to $106.00. This adjustment signals a positive outlook for the company, consistent with other recent analyst upgrades from firms like JP Morgan and Evercore ISI Group. BridgeBio Pharma, a biotechnology firm specializing in genetic diseases, is anticipated to have an average target price of $99.72 from 21 analysts, suggesting a 40.89% upside from its current price.
BBIO PE Ratio & Valuation, Is BBIO Overvalued
This article analyzes BridgeBio Pharma Inc. (BBIO) valuation, concluding that it is currently in the "Fair zone" based on its forward PS ratio compared to its five-year average. The fair price is estimated between $40.70 and $464.71 using a relative valuation method. Despite a P/S ratio above the industry average, the company's significant revenue growth of 2521.18% suggests this premium is sustainable.
BridgeBio Pharma CEO Kumar Neil sells $5.5m in BBIO stock
BridgeBio Pharma CEO Kumar Neil, through trusts, sold 70,185 shares of common stock for approximately $5.5 million on March 12 and 13, 2026. These sales were executed under a pre-arranged Rule 10b5-1 trading plan. The transactions follow a significant 115% surge in BBIO shares over the past year, with recent positive news including promising Phase 3 trial data for BBP-418 and favorable analyst ratings.
(BBIO) Risk Channels and Responsive Allocation
The article provides a detailed analysis of Bridgebio Pharma Inc. (BBIO) with strong sentiment supporting an overweight bias. It highlights an exceptional risk-reward setup targeting an 11.9% gain versus 0.3% risk. Three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are outlined with specific entry, target, and stop-loss levels.
Fred Alger Management LLC Has $10.25 Million Stake in BridgeBio Pharma, Inc. $BBIO
Fred Alger Management LLC significantly increased its stake in BridgeBio Pharma (NASDAQ:BBIO) by 729.3% in the third quarter, now holding 197,365 shares valued at $10.25 million. Despite institutional investors owning 99.85% of the company, corporate insiders have been net sellers, offloading approximately $16.6 million worth of shares. BridgeBio Pharma, with a $13.77 billion market cap, missed its last EPS estimate but reported strong revenue growth and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $83.95.
BridgeBio (BBIO) CEO’s family trusts sell 80,000 company shares
BridgeBio Pharma CEO Neil Kumar's family trusts sold a total of 80,000 BridgeBio common shares on March 12 and 13, 2026. These sales, executed under a Rule 10b5-1 trading plan, occurred at prices ranging from the high-$60s to approximately $70.18 per share. Following these transactions, the trusts continue to hold substantial indirect ownership in the company, while Kumar also retains direct ownership of 234,451 shares.
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock
BridgeBio Pharma CEO Neil Kumar recently sold 40,000 shares of the company's stock for $2.75 million, which represents a 5.75% reduction in his stake. This sale is part of a series of insider transactions by Kumar since January, totaling approximately 148,053 shares and raising about $10.6 million. Despite these insider sales and a recent EPS miss, analysts generally maintain a "Moderate Buy" rating for BBIO with a consensus price target of $83.95.
Granahan Investment Management LLC Buys 78,588 Shares of BridgeBio Pharma, Inc. $BBIO
Granahan Investment Management LLC has significantly increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 95.0%, purchasing an additional 78,588 shares and now owning 161,278 shares valued at $8,377,000. This comes as BridgeBio Pharma's stock has seen a 2.1% increase, trading at $69.41, despite missing analysts' earnings estimates, with the company's revenue up 2521.2% year-over-year. Institutional investors hold 99.85% of the stock, while company insiders have recently sold shares totaling over $13 million.
HighVista Strategies LLC Raises Holdings in BridgeBio Pharma, Inc. $BBIO
HighVista Strategies LLC significantly increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 21.4% in the third quarter, now holding 81,959 shares valued at $4.26 million. The company's stock has shown recent volatility but is up 2.1% with a market cap of $13.46 billion, despite missing EPS consensus in its latest earnings report while revenue surged over 2500% year-over-year. Analysts widely rate BBIO as a "Moderate Buy" with an average target price of $83.95, even as insiders have sold shares totaling over $13.8 million in the past 90 days.
Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO
Cinctive Capital Management LP reduced its stake in BridgeBio Pharma (NASDAQ:BBIO) by 50.8% in the third quarter, selling 98,688 shares and retaining 95,672 shares valued at $4.969 million. Institutional investors own 99.85% of the stock, and analysts have a "Moderate Buy" consensus rating with a target price of $83.95. BridgeBio Pharma, a clinical-stage biopharmaceutical company, recently reported quarterly earnings of ($1.00) EPS, missing estimates, but saw a 2521.2% year-over-year revenue increase.
Boone Capital Management LLC Buys Shares of 460,282 BridgeBio Pharma, Inc. $BBIO
Boone Capital Management LLC has acquired 460,282 shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO), valued at approximately $23.9 million, making it their 5th largest holding. Despite this institutional buying, some insiders have recently sold shares, though insiders still collectively own 18.2% of the company. Wall Street analysts are largely bullish on BridgeBio Pharma, with a consensus "Moderate Buy" rating and an average target price of $83.95.
BBIO6336503 Bond Risk Analysis
This article provides a risk analysis for the BBIO6336503 bond, issued by BridgeBio Pharma, Inc. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate the bond's reliability. The article also mentions access to exclusive analyst ratings for bonds.
How Positive Phase 3 LGMD Data Could Shape BridgeBio Pharma’s (BBIO) Risk Profile and Upside Potential
BridgeBio Pharma (BBIO) recently presented positive interim Phase 3 data for BBP-418 in LGMD2I/R9, showing broad efficacy and a favorable safety profile, paving the way for a Q1 2026 FDA filing. This data strengthens BBP-418's role as a near-term catalyst and helps diversify BridgeBio's revenue streams beyond its current reliance on Attruby, although high cash burn and net losses remain significant risks. The results also align with expectations for BBP-418 to be the first approved therapy for any form of limb-girdle muscular dystrophy.
BridgeBio director sells 8,671 shares after option exercise | BBIO SEC Filing - Form 4
BridgeBio Pharma director Hannah Valantine exercised stock options to acquire 8,671 shares of common stock at $27.36 per share on March 10, 2026. She subsequently sold all these shares at $72.00 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Valantine maintains an equity stake, holding 7,465 shares directly and 398 shares indirectly through her spouse.
BridgeBio Looks At Genetic Testing To Build Out BBP-418 Launch In LGMD2I/R9
BridgeBio Pharma is focusing on genetic testing to support the upcoming launch of its drug BBP-418 for LGMD2I/R9. This strategy aims to identify potential patients and streamline the commercialization process for the rare disease treatment. The company is leveraging these efforts to prepare for the drug's market entry effectively.
A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility
BridgeBio Pharma (BBIO) has seen recent share price volatility, including a 3.9% decline in the past day, yet boasts over 100% total shareholder return over the last year. Despite a current price of $71.39 against a target of $99.96, the company is considered 28.6% undervalued based on a narrative that highlights its strong product revenue from Attruby and recent positive Phase 3 readouts for other programs. However, its high P/S ratio of 27.6x raises questions about potential overvaluation based on current sales.
BridgeBio (BBIO) Reports Wider Q4 Loss of $1/Share vs $0.63 Estimate; Stock Surges 13%
BridgeBio Pharma (BBIO) reported a wider-than-expected Q4 2025 loss of $1 per share, against an estimated $0.62 loss, with a net loss of $192.9 million. Despite this earnings miss, the stock surged 13.2% to $74.32, indicating investors might be focusing on the company's revenue of $154.2 million and its future potential. The company faces significant leverage with $1.86 billion in debt and negative stockholders' equity, though its $14.4 billion market capitalization suggests investor confidence in its long-term prospects.
HC Wainwright Raises Earnings Estimates for BridgeBio Pharma
HC Wainwright has adjusted its earnings estimates for BridgeBio Pharma, slightly raising Q1 2026 EPS to ($0.61) while trimming FY2026 estimates to ($1.76), indicating near-term risk. However, the firm maintains a "Buy" rating and a $100 price target, projecting profitability in FY2027 with an estimated EPS of $1.83. This comes after BridgeBio reported mixed Q4 results, missing EPS estimates but exceeding revenue expectations, which led to a 13% stock jump and multiple price target upgrades from other firms.
